BR112022021845A2 - Inibidores de aldose redutase para tratar deficiência em sorbitol desidrogenase - Google Patents

Inibidores de aldose redutase para tratar deficiência em sorbitol desidrogenase

Info

Publication number
BR112022021845A2
BR112022021845A2 BR112022021845A BR112022021845A BR112022021845A2 BR 112022021845 A2 BR112022021845 A2 BR 112022021845A2 BR 112022021845 A BR112022021845 A BR 112022021845A BR 112022021845 A BR112022021845 A BR 112022021845A BR 112022021845 A2 BR112022021845 A2 BR 112022021845A2
Authority
BR
Brazil
Prior art keywords
reductase inhibitors
aldose reductase
treat
dehydrogenase deficiency
sorbitol dehydrogenase
Prior art date
Application number
BR112022021845A
Other languages
English (en)
Portuguese (pt)
Inventor
Shendelman Shoshana
Original Assignee
Applied Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Therapeutics Inc filed Critical Applied Therapeutics Inc
Publication of BR112022021845A2 publication Critical patent/BR112022021845A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112022021845A 2020-05-01 2021-04-27 Inibidores de aldose redutase para tratar deficiência em sorbitol desidrogenase BR112022021845A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063019186P 2020-05-01 2020-05-01
US202063019738P 2020-05-04 2020-05-04
PCT/US2021/029286 WO2021222165A1 (en) 2020-05-01 2021-04-27 Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency

Publications (1)

Publication Number Publication Date
BR112022021845A2 true BR112022021845A2 (pt) 2022-12-20

Family

ID=75954272

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021845A BR112022021845A2 (pt) 2020-05-01 2021-04-27 Inibidores de aldose redutase para tratar deficiência em sorbitol desidrogenase

Country Status (11)

Country Link
US (2) US20230121312A1 (enExample)
EP (1) EP4135674A1 (enExample)
JP (2) JP7788399B2 (enExample)
KR (1) KR20230005944A (enExample)
CN (1) CN115996725A (enExample)
AU (1) AU2021264454A1 (enExample)
BR (1) BR112022021845A2 (enExample)
CA (1) CA3176768A1 (enExample)
IL (1) IL297779A (enExample)
MX (1) MX2022013658A (enExample)
WO (1) WO2021222165A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
CN113840825A (zh) 2019-04-01 2021-12-24 应用治疗公司 醛糖还原酶抑制剂
MX2021013511A (es) 2019-05-07 2022-02-23 Univ Miami Tratamiento y deteccion de neuropatias heredadas y trastornos asociados.
GB202400033D0 (en) 2024-01-02 2024-02-14 Nicolnson Tamara Therapy i
WO2025219948A1 (en) * 2024-04-17 2025-10-23 Assia Chemical Industries Ltd. Crystalline forms of govorestat

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
JPH0495025A (ja) 1990-08-08 1992-03-27 Asahi Chem Ind Co Ltd アルドースリダクターゼ阻害剤
US5464961A (en) 1993-09-10 1995-11-07 Olin Corporation Arcjet anode
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
CN1200106A (zh) 1995-08-28 1998-11-25 美国家用产品公司 苯氧基乙酸类化合物用作醛糖还原酶抑制剂和抗高血糖药
PL179170B1 (pl) 1995-09-15 2000-07-31 Inst Lekow Nowe zwiazki,pochodne genisteiny PL PL PL PL
ES2122764T3 (es) 1995-11-20 1998-12-16 Lilly Co Eli Inhibidor de la proteina quinasa c.
AU6473898A (en) * 1997-03-21 1998-10-20 Regents Of The University Of California, The Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors
GB9714274D0 (en) * 1997-07-08 1997-09-10 Zeneca Ltd Pharmaceutical composition
EP0982306A3 (en) 1998-08-21 2000-07-05 Pfizer Products Inc. Polymorph of zopolrestat monohydrate
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
WO2003105864A1 (en) 2002-06-13 2003-12-24 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
EP2065038A1 (en) * 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
HUE031506T2 (en) 2010-07-16 2017-07-28 Univ Columbia Aldose reductase inhibitors and their use
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
JP6500992B2 (ja) 2015-09-01 2019-04-17 株式会社村田製作所 コイル内蔵部品
ES2966094T3 (es) 2016-06-21 2024-04-18 Univ Columbia Compuestos 4-oxo-3,4-dihidrotieno[3,4-d]piridazina como inhibidores de la aldosa reductasa y métodos de uso de los mismos
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications

Also Published As

Publication number Publication date
US20230121312A1 (en) 2023-04-20
JP2023524504A (ja) 2023-06-12
CN115996725A (zh) 2023-04-21
MX2022013658A (es) 2023-03-01
AU2021264454A1 (en) 2022-12-08
WO2021222165A1 (en) 2021-11-04
CA3176768A1 (en) 2021-11-04
US20240238288A1 (en) 2024-07-18
JP7788399B2 (ja) 2025-12-18
EP4135674A1 (en) 2023-02-22
IL297779A (en) 2022-12-01
KR20230005944A (ko) 2023-01-10
JP2026012262A (ja) 2026-01-23

Similar Documents

Publication Publication Date Title
MX2022013658A (es) Inhibidores de la aldosa reductasa para tratar la deficiencia de sorbitol deshidrogenasa.
CL2021001529A1 (es) Combinación fungicida que comprende a) al menos un fungicida inhibidor de succinato deshidrogenasa, el cual es benzovindiflupyr, b) al menos un fungicida multisitio y c) al menos otro fungicida; composición que la comprende; y método para controlar enfermedades fúngicas (div. sol. 201902495).
BR112021017998A2 (pt) Métodos para a produção de plantas clonais
BR112023002575A2 (pt) Inibidores de sarm1
BRPI1010993A2 (pt) método e sistema que proporcionam um ajuste melhorado de dados para planejamento virtual.
BR112018009212A8 (pt) composição, semente tratada, e, método para controlar patógenos fúngicos agrícolas.
BRPI0815474A8 (pt) Método para produzir um alimento ou bebida à base de malte apropriado para consumo por um indivíduo com doença celíaca
CR11278A (es) Composiciones y metodos para bloquear la respuesta al etileno en plantas, utilizando la sal del acido 3-cicloprop-1-enil-propanoico
MX2019014806A (es) Mitocetoscinas: agentes terapeuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en celulas cancerosas.
CL2022002410A1 (es) Terapia combinada de inhibidores axl/mer y pd-1/pd-l1.
BR112017026015A2 (pt) método para identificar e/ou selecionar uma planta de milho com resistência à podridão de colmo causada por antracnose, e método para introgredir um alelo qtl associado à resistência à podridão de colmo causada por antracnose em uma planta de milho
CL2009000730A1 (es) Metodo implementado en ordenador para generar ficheros interrelacionados, que comprende verificacion de una coherencia; sistema.
BR112018073651A2 (pt) reguladores do crescimento de planta e métodos para o seu uso
Gao et al. Quantifying the impacts of environmental stress factors on biogenic volatile organic compound emissions in China
BR112017011246A2 (pt) composições e métodos para introdução de micronutriente
MX2024002431A (es) Estabilizacion mejorada de ficocianinas en composiciones acidas.
BR112022025619A2 (pt) Composição de controle de artrópode
BRPI0616848A8 (pt) Semente de planta transgênica com maior teor de lisina
BR112018009738A2 (pt) biomarcadores para tratamento contra o câncer com apilimod
MX2024007706A (es) Plantas para producir cannabinoides.
BR112023015156A2 (pt) Composição para uso na degradação ou prevenção da formação de biofilme
MX2023004203A (es) Plantas de sandia partenocarpicas.
BR112015026276A2 (pt) processo para aprimorar degumagem enzimática aquosa de óleos vegetais
Martínez-Sancho et al. Distinct effects of water use efficiency increase on growth in Scots pine and sessile oak in the Mediterranean Basin
BR112023024858A2 (pt) Plantas de gergelim resistentes a herbicidas que inibem acetolactato sintase, composições e métodos para produzir as mesmas

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122025019642-8 PROTOCOLO 870250082946 EM 15/09/2025 16:04.